Immudex Usa, LLC
Fairfax, VA
- UEI
- TBNLHW1MFEJ1
- CAGE
- 63GQ8
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 10615 Judicial Dr #402, Fairfax, VA 22030, USA
- Website
- immudex.com
- Founded
- 2009
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $77,450 |
| FY2025 | $0 |
| FY2024 | $11,109 |
| FY2023 | $47,575 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $77,450 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Immudex USA, LLC, a foreign-owned for-profit corporation based in Fairfax, Virginia, manufactures and supplies specialized immunology research reagents — dextramers, T-cell receptor constructs, and MHC Class II reagents — to the National Institutes of Health and its component institutes as a prime contractor on unset-aside purchase orders and blanket purchase agreements. The vendor operates exclusively in the prime role (100% of recent awards) and competes full-and-open without set-aside designations.
Immudex's federal footprint is concentrated entirely within the Department of Health and Human Services National Institutes of Health. The National Institute of Allergy and Infectious Diseases accounts for seven awards valued at $74 thousand combined potential value; the Office of Logistics and Acquisition Operations holds two awards totaling $10 million combined potential value, anchored by a single-award blanket purchase agreement for blood and blood products with a $10 million ceiling running through October 2025; the National Cancer Institute holds two awards valued at $36 thousand combined potential value; and the National Institute on Drug Abuse holds one award valued at $52 thousand. Representative work includes a $47,575 purchase order from the National Institute of Allergy and Infectious Diseases (awarded September 2023) for custom T-cell receptor reagents supporting CD8 T-cell receptor function studies in HIV-1 and COVID-19; a $24,964 purchase order from the National Cancer Institute (July 2026) for custom MHC Class II HLA-DP xynapse and dextramer reagents for liver cancer neoantigen validation; and a $52,486 purchase order from the National Institute on Drug Abuse (September 2026) for DCODE dextramers for research applications.
Recent activity shows two awards in 2026, one in 2024, two in 2023, and three each in 2016 and 2017, reflecting episodic ordering patterns typical of research reagent supply. Two awards with combined potential value of $77 thousand are scheduled for completion within the next twenty-four months. The vendor's primary NAICS concentrations are Pharmaceutical Preparation Manufacturing and In-Vitro Diagnostic Substance Manufacturing, with PSC coding under Drugs and Biologicals. The disparity between combined potential value ($10.2 million) and combined dollars obligated ($162 thousand, 2% of potential) reflects the vendor's position on the $10 million BPA, which carries ceiling authority but lower invoiced commitments to date.
Quick answers
Is Immudex Usa, LLC registered in SAM.gov?
Yes. Immudex Usa, LLC's SAM.gov registration is active through October 29, 2027.
What is Immudex Usa, LLC's CAGE code?
Immudex Usa, LLC's CAGE code is 63GQ8, and its Unique Entity ID (UEI) is TBNLHW1MFEJ1.
How much has Immudex Usa, LLC received in federal contracts?
Federal contracts obligated $136,135 to Immudex Usa, LLC in fiscal years 2023 through 2027.
What is Immudex Usa, LLC's most recent federal award?
Immudex Usa, LLC's most recent federal contract award is Dcode dextramer. 30 days ARO (75N98026P01802), from Office of Logisitics and Acquisition Operations (NIH), on September 23, 2026.
On GovTribe
See Immudex Usa, LLC's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors